glp 1 in obesity GLP-1 Agonist to Treat and Prevent Cardiovascular Disease: What Have We Achieved so Far? | Current Atherosclerosis Reports GLP-1R Agonists for Weight Loss

And I started thinking that there was a pattern there that needed to be investigated. You found a 1.5% increase in hypotension in patients six months after starting GLP-1s

As employers grapple with how to pay for these medications, some are exploring strategies like: Limiting coverage to patients with the highest need Pairing GLP-1 coverage with a dietician to improve nutrition, support for physical exercise and intensive behavioral health therapy Alternative payment models that hold drug manufacturers accountable for producing results GLP-1s deliver impressive clinical results but at a steep cost

That means they can be more sensitive to substances compared to adults

Loyo P, Bohra C, Bhatia K, Baruch L, Eng C, Peters JJ